SGX PHARMACEUTICALS, INC. 3
3 · SGX PHARMACEUTICALS, INC. · Filed Apr 14, 2008
Insider Transaction Report
Form 3
BVF PARTNERS L P/IL
10% OwnerOther
Holdings
- 508,700
Common Stock
- 1,847,200
Common Stock
- 748,417
Common Stock
- 3,104,317(indirect: See footnotes)
Common Stock
Footnotes (6)
- [F1]The shares of Common Stock are directly beneficially owned by Biotechnology Value Fund, L.P., a Delaware limited partnership ("BVF").
- [F2]The shares of Common Stock are directly beneficially owned by Biotechnology Value Fund, II, L.P., a Delaware limited partnership ("BVF2").
- [F3]The shares of Common Stock are directly beneficially owned by BVF Investments, LLC, a Delaware limited liability company ("Investments").
- [F4]The shares of Common Stock are indirectly beneficially owned by BVF Partners L.P., a Delaware limited partnership ("Partners"). Partners is the general partner of BVF and BVF2, and is the manager of Investments.
- [F5]The shares of Common Stock are indirectly beneficially owned by BVF Partners L.P., a Delaware corporation ("BVF Inc."), which is the general partner of Partners and is also an investment advisor to Partners.
- [F6]Pursuant to the operating agreement of Investments, Partners is authorized, among other things, to invest funds of Ziff Asset Management, L.P., the majority member of Investments, in the shares of Common Stock described herein and to vote and exercise dispositive power over those securities. Mark N. Lampert is the sole shareholder and sole director of BVF Inc., and is an officer of BVF Inc. This joint filing on Form 3 shall not be deemed an admission that Mark N. Lampert is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise, the beneficial owner of any securities covered by this joint filing. Mr. Lampert disclaims beneficial ownership of all securities reported in this joint filing on Form 3, except to the extent that he has a pecuniary interest therein.